Details Consolidated financial statements for the period ended 30 June 2020Consolidated Financial Statements resultsBy adminAugust 16, 2020
Disclosure to EGX regarding the company’s board composition Regulatory DisclosuresBy adminAugust 5, 2020
Rameda notified of Anviziram, Remdesivir-Rameda vial prices by Egyptian Drug Authority, on track to market first Remdesivir-Rameda production in September 2020 Corporate NewsBy adminJuly 20, 2020
Rameda commences manufacture of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Corporate NewsBy adminJune 22, 2020
EGX disclosure regarding Rameda’s manufacturing of “Anviziram” Tablets the Generic Equivalent of Japanese antiviral Avigan for treatment of Covid-19 patients and receives approval from Egyptian Drug Authority to manufacture Remedsivir Regulatory DisclosuresBy adminJune 22, 2020
